Uncategorized

FDA approves first anticoagulant for VTE in pediatric patients

On May 16, the FDA approved Fragmin (dalteparin sodium) injection to reduce the recurrence of symptomatic venous thromboembolism (VTE) in pediatric patients 1 month of age and older.

 

Read more at fda.gov.

Poll

Recent Posts